Diagnostic Products teams up with Compugen
This article was originally published in Clinica
Executive Summary
Compugen has agreed to give Diagnostic Products, a Los Angeles, California-based immunodiagnostic testing company, access to its portfolio of biomarkers, which the latter will use for developing and commercialising immunoassay and DNA-based diagnostic products. In return, Tel Aviv, Israel-based Compugen will receive development milestone payments and royalties on the sales of these products. In addition, the two companies are to collaborate on discovering new biomarker candidates for both therapeutic and diagnostic applications.